Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05840913
Other study ID # Articaine Efficacy for IANB
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 30, 2023
Est. completion date October 31, 2023

Study information

Verified date May 2023
Source Armed Forces Institute of Dentistry, Pakistan
Contact Kanza Zafar, BDS
Phone 00923337808809
Email kanzazafar6@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized clinical trial comparing the anaesthetic efficacy of 1.8 and 3.6 mL of Articaine for inferior alveolar nerve block when treating mandibular molars with Irreversible Pulpitis


Description:

An informed written consent of the patients will be obtained. (Annex-A). Demographic details (including name, age, gender, contact) will be obtained on data collection forms. (Annex-B). The principal investigator will perform the local anesthetic injection and the participants will be assigned to one of the groups. Group 1: 1.8 mL articaine Group 2: 3.6 mL articaine Before starting the treatment i.e. before administration of the anesthetic solution, each participant will receive an explanation regarding the Heft-Parker visual analog pain scale (VAS) and asked to rate their pain on a self-report questionnaire. A topical anesthetic gel (20% Benzocaine; Premier, Philadelphia, PA) will passively placed at the injection site with a cotton tip applicator for 1 minute before injection. A conventional IANB will administered using an aspirating syringe with a side-loading cartridge system (Dena Instruments; Forgeman Instruments Co, Sialkot, Pakistan) and a 27-G 31-mm needle (C-K ject; CK Dental, Kor-Kyungji-do, Korea). All injections will be given by one clinician in both groups. Group 2 participants will receive 2 cartridges of the anesthetic solution and group 1 will receive a cartridge of the anesthetic solution followed by a mock injection. The rest of the procedure will be performed by a second investigator. Ten minutes after injection, the participants will be asked whether they have lip numbness. Any patient without lip numbness at this stage will excluded from study. Fifteen minutes after the administration of the IANB, the teeth will be re-evaluated with electric pulp testing. On positive response, participants will be again asked to rate their pain using the HP VAS on the questionnaire. If higher than mild pain is reported, supplemental anesthesia (intraperiodontal ligament or intrapulpal injection) will be used to provide patient comfort throughout the treatment. Then teeth under study will be isolated with a rubber dam, and caries removed followed by the preparation of an endodontic access cavity. The participants will be informed to stop the practitioner at any stage of treatment if they feel more than mild pain by raising their hand. At the end of each stage of treatment (access cavity preparation, pulp chamber opening, root canal instrumentation), the practitioner will stop work and ask the participants to rate their pain if they do not raise their hand during treatment. The success will be defined as the ability to undertake pulp access and canal instrumentation with no or mild pain (Heft-Parker visual analog scale [HP VAS] score <55 mm) whereas moderate or severe pain will considered as failure of anesthesia.


Recruitment information / eligibility

Status Recruiting
Enrollment 78
Est. completion date October 31, 2023
Est. primary completion date October 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Healthy patients, including age group 18-55 years old - Mandibular first molar tooth with symptomatic irreversible pulpitis - Normal periapical radiographic appearance - Moderate pain on Heft-Parker VAS ( > 54 mm and < 114 mm ) - Lingering pain or prolonged response to the cold testing (more than 10 seconds) - Positive response to electric pulp testing Exclusion Criteria: - Patients who have taken analgesic or anti-inflammatory drugs within 6 hours before treatment visit - History of allergy to 4% articaine or epinephrine - Patients with systemic diseases - Pregnant or lactating patients - Teeth with severe periodontal disease - Teeth with periapical radiolucency - Any type of medication that could potentially interact with the anesthetic solution (antihypertensives)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge
Local anesthetic injection for intra- operative pain control

Locations

Country Name City State
Pakistan Armed Forces Institue Of Dentistry Rawalpindi Punjab
Pakistan Armed Forces Institute of Dentistry Rawalpindi Punjab

Sponsors (1)

Lead Sponsor Collaborator
Armed Forces Institute of Dentistry, Pakistan

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Control Pain recordings on a self-report questionnaire using Heft-Parker Visual Analogue Scale.
The scores are divided into 4 categories:
No pain 0 mm Mild pain > 0 mm and = 54 mm Moderate pain > 54 mm and < 114 mm Severe Pain = 114 mm
The success will be defined as the ability to undertake pulp access and canal instrumentation with no or mild pain (Heft-Parker visual analog scale [HP VAS] score <55 mm) whereas moderate or severe pain will considered as failure of anesthesia.
30 to 45 minutes
See also
  Status Clinical Trial Phase
Completed NCT04235894 - An Observer Rating Scale of Facial Expression Can Predict Dreaming in Propofol Anesthesia
Completed NCT04166890 - Comparison of the Efficacy and Safety of Two Homologous Active Principles for Local Dental Anesthesia Phase 4
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Recruiting NCT04037774 - Comparision of Different Doses of Dexmedetomidine With Low Dose Bupivacaine in Selective Spinal Anesthesia. Phase 4
Recruiting NCT05113420 - The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations
Completed NCT03801629 - Neuroimmune Effects of Opioid Administration Phase 1
Completed NCT04052776 - Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES Phase 1
Completed NCT04037085 - Ketamine to Improve Recovery After Cesarean Delivery - Part 1 Phase 2
Completed NCT05050071 - Evaluation of Antibacterial Effect of Allium Sativum, Calcium Hydroxide and Their Combination in Infected Mature Teeth Phase 2/Phase 3
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Completed NCT06238154 - Flurbiprofen Tablet vs Spray In Oral Soft Tissue Wounds Phase 4
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Recruiting NCT05300152 - Pulpotomy Medications in Primary Teeth N/A
Recruiting NCT04594889 - Comparison of Sirolimus vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia N/A
Not yet recruiting NCT05018936 - Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Phase 2/Phase 3
Completed NCT04245774 - Comparing the Effects of Levobupivacaine and Bupivacaine in Saddle Spinal Anesthesia Phase 4
Completed NCT04449536 - Cysteine-lowering Treatment With Mesna Phase 1
Recruiting NCT05975255 - Dose Finding Study for Remimazolam in Children Phase 2
Active, not recruiting NCT04254731 - Effects of Switching From Racemic Methadone to R-methadone on QTc Intervals Phase 4
Completed NCT03635684 - Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen Phase 2